Literature DB >> 6113122

Sulfoxide reduction. In vitro reduction of sulindac by rat hepatic cytosolic enzymes.

J H Ratnayake, P E Hanna, M W Anders, D E Duggan.   

Abstract

The reductive biotransformation of sulindac to the corresponding sulfide has been characterized in vitro in rat preparations with respect to subcellular and tissue distribution, cofactor requirements, kinetic constants, and the effects of inhibitors. The highest activity was found in hepatic and renal cytosolic fractions. Either NADPH or dithiothreitol effectively supported the reaction but NADH was much less effective. The KM and Vmax for sulindac were found to be 36.7 +/- 3.8 microM and 75.7 +/- 9.7 pmol/min/mg of protein, respectively, and the KM and Vmax for NADPH were found to be 0.48 +/- 0.03 microM and 43.3 +/- 4.6 pmol/min/mg of protein, respectively. The most effective inhibitors of the reaction were sulfhydryl reagents and sulfoxides structurally related to sulindac.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6113122

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  7 in total

1.  The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine.

Authors:  G Xie; T Nie; G G Mackenzie; Y Sun; L Huang; N Ouyang; N Alston; C Zhu; O T Murray; P P Constantinides; L Kopelovich; B Rigas
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

2.  Validation of a column-switching high-performance liquid chromatographic (HPLC) method for determination of ML-1035 and its five metabolites in plasma.

Authors:  B S Kuo; J C Poole; K K Hwang
Journal:  Pharm Res       Date:  1992-01       Impact factor: 4.200

Review 3.  Clinical pharmacokinetics of sulindac. A dynamic old drug.

Authors:  N M Davies; M S Watson
Journal:  Clin Pharmacokinet       Date:  1997-06       Impact factor: 6.447

4.  The in vitro metabolism of phospho-sulindac amide, a novel potential anticancer agent.

Authors:  Gang Xie; Ka-Wing Cheng; Liqun Huang; Basil Rigas
Journal:  Biochem Pharmacol       Date:  2014-07-18       Impact factor: 5.858

5.  Population Pharmacokinetics of Sulindac and Genetic Polymorphisms of FMO3 and AOX1 in Women with Preterm Labor.

Authors:  Jin Won Sung; Hwi-Yeol Yun; Sunny Park; Young Ju Kim; Jeong Yee; Kyung Eun Lee; Byungjeong Song; Jee Eun Chung; Hye Sun Gwak
Journal:  Pharm Res       Date:  2020-01-28       Impact factor: 4.200

6.  Studies on the metabolism and biological activity of the epimers of sulindac.

Authors:  David Brunell; Daphna Sagher; Shailaja Kesaraju; Nathan Brot; Herbert Weissbach
Journal:  Drug Metab Dispos       Date:  2011-03-07       Impact factor: 3.922

7.  Pharmacokinetics and reversible biotransformation of sulfinpyrazone and its metabolites in rabbits. I. Single-dose study.

Authors:  W A Ritschel
Journal:  Pharm Res       Date:  1986-06       Impact factor: 4.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.